Cargando…
_version_ 1783411862457548800
author Cifaldi, Cristina
Brigida, Immacolata
Barzaghi, Federica
Zoccolillo, Matteo
Ferradini, Valentina
Petricone, Davide
Cicalese, Maria Pia
Lazarevic, Dejan
Cittaro, Davide
Omrani, Maryam
Attardi, Enrico
Conti, Francesca
Scarselli, Alessia
Chiriaco, Maria
Di Cesare, Silvia
Licciardi, Francesco
Davide, Montin
Ferrua, Francesca
Canessa, Clementina
Pignata, Claudio
Giliani, Silvia
Ferrari, Simona
Fousteri, Georgia
Barera, Graziano
Merli, Pietro
Palma, Paolo
Cesaro, Simone
Gattorno, Marco
Trizzino, Antonio
Moschese, Viviana
Chini, Loredana
Villa, Anna
Azzari, Chiara
Finocchi, Andrea
Locatelli, Franco
Rossi, Paolo
Sangiuolo, Federica
Aiuti, Alessandro
Cancrini, Caterina
Di Matteo, Gigliola
author_facet Cifaldi, Cristina
Brigida, Immacolata
Barzaghi, Federica
Zoccolillo, Matteo
Ferradini, Valentina
Petricone, Davide
Cicalese, Maria Pia
Lazarevic, Dejan
Cittaro, Davide
Omrani, Maryam
Attardi, Enrico
Conti, Francesca
Scarselli, Alessia
Chiriaco, Maria
Di Cesare, Silvia
Licciardi, Francesco
Davide, Montin
Ferrua, Francesca
Canessa, Clementina
Pignata, Claudio
Giliani, Silvia
Ferrari, Simona
Fousteri, Georgia
Barera, Graziano
Merli, Pietro
Palma, Paolo
Cesaro, Simone
Gattorno, Marco
Trizzino, Antonio
Moschese, Viviana
Chini, Loredana
Villa, Anna
Azzari, Chiara
Finocchi, Andrea
Locatelli, Franco
Rossi, Paolo
Sangiuolo, Federica
Aiuti, Alessandro
Cancrini, Caterina
Di Matteo, Gigliola
author_sort Cifaldi, Cristina
collection PubMed
description Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders. Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes. Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: T cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology. Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% (n = 30) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrent method was highly successful for those cases with well-defined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage. Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene.
format Online
Article
Text
id pubmed-6470723
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64707232019-04-26 Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies Cifaldi, Cristina Brigida, Immacolata Barzaghi, Federica Zoccolillo, Matteo Ferradini, Valentina Petricone, Davide Cicalese, Maria Pia Lazarevic, Dejan Cittaro, Davide Omrani, Maryam Attardi, Enrico Conti, Francesca Scarselli, Alessia Chiriaco, Maria Di Cesare, Silvia Licciardi, Francesco Davide, Montin Ferrua, Francesca Canessa, Clementina Pignata, Claudio Giliani, Silvia Ferrari, Simona Fousteri, Georgia Barera, Graziano Merli, Pietro Palma, Paolo Cesaro, Simone Gattorno, Marco Trizzino, Antonio Moschese, Viviana Chini, Loredana Villa, Anna Azzari, Chiara Finocchi, Andrea Locatelli, Franco Rossi, Paolo Sangiuolo, Federica Aiuti, Alessandro Cancrini, Caterina Di Matteo, Gigliola Front Immunol Immunology Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders. Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes. Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: T cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology. Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% (n = 30) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrent method was highly successful for those cases with well-defined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage. Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene. Frontiers Media S.A. 2019-04-11 /pmc/articles/PMC6470723/ /pubmed/31031743 http://dx.doi.org/10.3389/fimmu.2019.00316 Text en Copyright © 2019 Cifaldi, Brigida, Barzaghi, Zoccolillo, Ferradini, Petricone, Cicalese, Lazarevic, Cittaro, Omrani, Attardi, Conti, Scarselli, Chiriaco, Di Cesare, Licciardi, Davide, Ferrua, Canessa, Pignata, Giliani, Ferrari, Fousteri, Barera, Merli, Palma, Cesaro, Gattorno, Trizzino, Moschese, Chini, Villa, Azzari, Finocchi, Locatelli, Rossi, Sangiuolo, Aiuti, Cancrini and Di Matteo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Cifaldi, Cristina
Brigida, Immacolata
Barzaghi, Federica
Zoccolillo, Matteo
Ferradini, Valentina
Petricone, Davide
Cicalese, Maria Pia
Lazarevic, Dejan
Cittaro, Davide
Omrani, Maryam
Attardi, Enrico
Conti, Francesca
Scarselli, Alessia
Chiriaco, Maria
Di Cesare, Silvia
Licciardi, Francesco
Davide, Montin
Ferrua, Francesca
Canessa, Clementina
Pignata, Claudio
Giliani, Silvia
Ferrari, Simona
Fousteri, Georgia
Barera, Graziano
Merli, Pietro
Palma, Paolo
Cesaro, Simone
Gattorno, Marco
Trizzino, Antonio
Moschese, Viviana
Chini, Loredana
Villa, Anna
Azzari, Chiara
Finocchi, Andrea
Locatelli, Franco
Rossi, Paolo
Sangiuolo, Federica
Aiuti, Alessandro
Cancrini, Caterina
Di Matteo, Gigliola
Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
title Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
title_full Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
title_fullStr Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
title_full_unstemmed Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
title_short Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
title_sort targeted ngs platforms for genetic screening and gene discovery in primary immunodeficiencies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470723/
https://www.ncbi.nlm.nih.gov/pubmed/31031743
http://dx.doi.org/10.3389/fimmu.2019.00316
work_keys_str_mv AT cifaldicristina targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT brigidaimmacolata targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT barzaghifederica targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT zoccolillomatteo targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT ferradinivalentina targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT petriconedavide targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT cicalesemariapia targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT lazarevicdejan targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT cittarodavide targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT omranimaryam targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT attardienrico targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT contifrancesca targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT scarsellialessia targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT chiriacomaria targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT dicesaresilvia targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT licciardifrancesco targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT davidemontin targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT ferruafrancesca targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT canessaclementina targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT pignataclaudio targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT gilianisilvia targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT ferrarisimona targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT fousterigeorgia targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT bareragraziano targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT merlipietro targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT palmapaolo targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT cesarosimone targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT gattornomarco targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT trizzinoantonio targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT moscheseviviana targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT chiniloredana targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT villaanna targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT azzarichiara targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT finocchiandrea targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT locatellifranco targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT rossipaolo targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT sangiuolofederica targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT aiutialessandro targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT cancrinicaterina targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies
AT dimatteogigliola targetedngsplatformsforgeneticscreeningandgenediscoveryinprimaryimmunodeficiencies